Oral vaccine for COVID-19 and influenza

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of protein-based vaccines for COVID-19 and influenza administered orally or sublingually, as opposed to the traditional intramuscular route. Participants will receive both vaccines over a four-month period in a cross-over design, allowing for direct comparison of their immune responses. The study aims to address the waning immunity observed with current vaccines, particularly against newer variants of COVID-19. The oral delivery method could potentially enhance accessibility and compliance for vaccination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able to provide written informed consent
* Males or females 18 years of age or older
* Understand and are likely to comply with planned study procedures and be available for all study visits.
* Do not plan to have a non-study COVID-19 or influenza vaccine within the next 6 months.

Exclusion Criteria:

* Allergy to COVID-19 or seasonal influenza vaccine or one of its components e.g. polysorbate 80.
* Have received a COVID-19 or influenza vaccine or an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent or a COVID-19 or influenza vaccine during the trial reporting period.
* Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.

Where it's running

• Arasmi
  Adelaide, South Australia, Australia Recruiting

Study contacts

• Principal investigator: Dimitar Sajkov, MBBS/PhD — Arasmi
• Study coordinator: Sharen Pringle, GradCert
• Email: office@arasmi.org
• Phone: 0437033400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Influenza vaccine based on mRNA in adults 18-64

  A vaccine made with mRNA is being tested in adults 18 to 64 to see if it triggers a good immune response and is safe.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Glendale, Arizona and 11 other locations · NCT07851246

• Baloxavir for preventing flu after exposure in household contacts

  A single dose of baloxavir marboxil is being tested to see if it prevents symptomatic, lab-confirmed influenza in people who live with someone who has flu symptoms.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Guangzhou, Guangdong and 7 other locations · NCT07827599

• Influenza vaccine study for adults 65 and older

  A vaccine trial tests an investigational mRNA flu shot against a licensed flu vaccine in adults 65+ to see if it better prevents flu during the season.

  Recruiting at 163 sites Phase 3 GlaxoSmithKline · Anniston, Alabama and 162 other locations · NCT07805707

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Testing a new quadrivalent influenza vaccine for safety and effectiveness

  This study is testing a new flu vaccine to see if it's safe and effective for adults aged 18 and older.

  Recruiting Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Shijiazhuang, Hebei · NCT06824519

• Evaluating a new treatment to prevent severe COVID-19 complications

  This study is testing a new treatment to see if it can help hospitalized COVID-19 patients avoid severe complications caused by inflammation.

  Recruiting at 3 sites Phase 1/2 Peaches Biotech · Alcalá de Henares, Madrid and 2 other locations · NCT06684379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.